Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
3 competitors in Prostatic Neoplasms
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Nubeqa
NUBEQA is indicated for the treatment of adult men with non‑metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1). metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1). metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1).
View on EMASuperficial Vein Thrombosis
Polypoidal Choroidal Vasculopathy
Pelvic Inflammatory Disease
Pulmonary Tuberculosis
Severe Sepsis